BACKGROUND: The pro-inflammatory cytokines, interleukin (IL)-18 and tumour necrosis factor-alpha (TNFalpha) may play a role in coronary heart disease (CHD). We aimed to extend data on their relationships to the risk of CHD in generally healthy populations. METHODS: During 5.5years follow-up in the Fletcher Challenge general population cohort there were 256 CHD cases, and 615 controls were matched for age and sex. Baseline plasma levels of IL-18 and TNFalpha were related to CHD risk in available samples (77%). RESULTS: Plasma levels of IL-18 (11% increase in mean, p=0.01) and TNFalpha (10% increase in mean p=0.024) were significantly elevated in CHD cases versus controls. In univariable models IL-18 was associated with CHD risk (odds ratio [OR] upper third to lower third, 1.63; 95% CI 1.08, 2.46), but TNFalpha was not (OR 1.33; 95% CI 0.87, 2.02).After adjusting for major CHD risk factors and CRP, the association of IL-18 with CHD risk was attenuated (OR 1.69; 95% CI 0.94, 3.03). CONCLUSIONS: IL-18, but not TNFalpha, had a non-negligible association with CHD risk, although the association of IL-18 with risk was weak after full adjustment. These cytokines may play a role in CHD pathology, but may not be robust risk biomarkers. 2010 Elsevier Ltd. All rights reserved.
BACKGROUND: The pro-inflammatory cytokines, interleukin (IL)-18 and tumour necrosis factor-alpha (TNFalpha) may play a role in coronary heart disease (CHD). We aimed to extend data on their relationships to the risk of CHD in generally healthy populations. METHODS: During 5.5years follow-up in the Fletcher Challenge general population cohort there were 256 CHD cases, and 615 controls were matched for age and sex. Baseline plasma levels of IL-18 and TNFalpha were related to CHD risk in available samples (77%). RESULTS: Plasma levels of IL-18 (11% increase in mean, p=0.01) and TNFalpha (10% increase in mean p=0.024) were significantly elevated in CHD cases versus controls. In univariable models IL-18 was associated with CHD risk (odds ratio [OR] upper third to lower third, 1.63; 95% CI 1.08, 2.46), but TNFalpha was not (OR 1.33; 95% CI 0.87, 2.02).After adjusting for major CHD risk factors and CRP, the association of IL-18 with CHD risk was attenuated (OR 1.69; 95% CI 0.94, 3.03). CONCLUSIONS:IL-18, but not TNFalpha, had a non-negligible association with CHD risk, although the association of IL-18 with risk was weak after full adjustment. These cytokines may play a role in CHD pathology, but may not be robust risk biomarkers. 2010 Elsevier Ltd. All rights reserved.
Authors: Barbara J M H Jefferis; Olia Papacosta; Christopher G Owen; S Goya Wannamethee; Steve E Humphries; Mark Woodward; Lucy T Lennon; Andrew Thomson; Paul Welsh; Ann Rumley; Gordon D O Lowe; Peter H Whincup Journal: Atherosclerosis Date: 2011-03-24 Impact factor: 5.162
Authors: Paul G Shiels; Liane M McGlynn; Alan MacIntyre; Paul C D Johnson; G David Batty; Harry Burns; Jonathan Cavanagh; Kevin A Deans; Ian Ford; Alex McConnachie; Agnes McGinty; Jennifer S McLean; Keith Millar; Naveed Sattar; Carol Tannahill; Yoga N Velupillai; Chris J Packard Journal: PLoS One Date: 2011-07-27 Impact factor: 3.240
Authors: Ben Schöttker; Christian Herder; Dietrich Rothenbacher; Michael Roden; Hubert Kolb; Heiko Müller; Hermann Brenner Journal: Diabetes Care Date: 2013-02-01 Impact factor: 19.112
Authors: Barbara J Jefferis; Peter H Whincup; Paul Welsh; S Goya Wannamethee; Ann Rumley; Shah Ebrahim; Debbie A Lawlor; Gordon D O Lowe Journal: Cytokine Date: 2012-12-01 Impact factor: 3.861
Authors: Elizabeth A McKie; Juliet L Reid; Prafull C Mistry; Stephen L DeWall; Lee Abberley; Philip D Ambery; Blas Gil-Extremera Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240